Mr. Fred Colen reports

NEOVASC ANNOUNCES GERMAN REIMBURSEMENT RENEWAL AND COMMERCIAL PROGRESS

The German Institute for the Hospital Remuneration System (InEK) has awarded Neovasc Inc.'s Neovasc Reducer NUB Status 1 designation yet again for 2022. Additionally, the company announced the 500th patient has been treated in Germany.

New examination and treatment methods (NUBs) comprise novel and innovative medicines, medical products and procedures that can be utilized by hospitals before reaching full reimbursement eligibility. The NUB process opens the path for negotiations between hospitals and health insurers for the reimbursement of new medical treatments in the German health care system. InEK is responsible for prioritizing new therapies in Germany through the NUB process.

Reducer has been granted Status 1, the highest-priority designation available. The NUB decision is valid for one year and can be renewed annually. For 2022, 256 German hospitals applied for the Reducer NUB, and they can now negotiate full reimbursement coverage for the Reducer therapy.

"Our team has been focused on securing broad reimbursement coverage for Reducer so more patients can benefit from the therapy," commented Fred Colen, chief executive officer of Neovasc. "Obtaining NUB Status 1 for 2022 from the German reimbursement authorities is a vital component of our overall strategy. In the past several quarters, we have had significant reimbursement wins in Germany, France, the U.K. and the United States. These reimbursement expansions are a testament to the profound impact that the Reducer can have on patients."

The 500th patient treated with the Reducer in Germany

The cardiology team at Helios-Kliniken, Schwerin, Germany, recently completed the 500th implant of the Reducer in Germany. The procedure marks another meaningful step as the company continues to expand adoption of the procedure. Prof. Alexander Staudt, director of cardiology, and Dr. Philipp Hammer performed the procedure.

"We are extremely grateful to be able to offer this treatment for our patients with chronic refractory angina," commented Prof. Staudt. "Prior to the availability of the Reducer, we struggled to treat these patients. Now, we have a reliable treatment option that offers them hope."

About Reducer

The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. Reducer is investigational in the United States in the COSIRA-II clinical trial. Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, affects millions of patients worldwide, who typically lead severely restricted lives because of their disabling symptoms. The Reducer is designed to alter blood flow within the myocardium of the heart and increase the perfusion of oxygenated blood to ischemic areas of the heart muscle, which may provide relief of angina symptoms.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.

We seek Safe Harbor.